共 43 条
[1]
PI3K/Akt/mTOR inhibitors in breast cancer[J]. Joycelyn JX Lee,Kiley Loh,Yoon-Sim Yap.Cancer Biology & Medicine. 2015(04)
[2]
Regulation of the m RNA half-life in breast cancer[J]. Paola Griseri,Gilles Pagès.World Journal of Clinical Oncology. 2014(03)
[4]
Analysis of PI3K/mTOR pathway biomarkers and their prognostic value in women with hormone receptor positive HER2 negative early breast cancer[J] . Hamdy A. Azim,Loay Kassem,Isabelle Treilleux,Qing Wang,Mona Abu El Enein,Shady E. Anis,Thomas Bachelot.Translational Oncology . 2016
[5]
Better Together: Targeted Combination Therapies in Breast Cancer[J] . Elisa Zanardi,Giacomo Bregni,Filippo de Braud,Serena Di Cosimo.Seminars in Oncology . 2015 (6)
[8]
Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease[J] . Murugan Kalimutho,Kate Parsons,Deepak Mittal,J. Alejandro López,Sriganesh Srihari,Kum Kum Khanna.Trends in Pharmacological Sciences . 2015 (12)
[10]
Enhancing Endocrine Therapy for Hormone Receptor–Positive Advanced Breast Cancer: Cotargeting Signaling Pathways[J] . Johnston Stephen R. D..JNCI Journal of the National Cancer Institute . 2015 (10)